Development and Manufacturing Solutions
Integrated Development & Manufacturing Solutions for Confident Clinical and Commercial Progression
At PI Health Sciences, our integrated Development and Manufacturing Solutions are designed to bridge late discovery, process development, and GMP manufacturing within a unified scientific and operational framework. We support programs from route optimization and analytical validation through preclinical, clinical, and commercial supply while systematically reducing technical, regulatory, and scale-up risk.
Our model integrates Process R&D, Analytical Sciences, Process Safety, and phase-appropriate manufacturing to ensure exposure, quality, scalability, and compliance are evaluated together rather than in isolation. This coordinated approach enables informed development decisions, seamless technology transfer, and efficient advancement toward commercial readiness.
By combining scalable chemistry, safety-aligned process design, regulatory-compliant analytical strategies, and controlled EU GMP production, we deliver development and manufacturing programs that are scientifically robust, operationally efficient, and submission-ready across global markets.
Development Services
Process R&D
Advancing APIs from early route design to scalable manufacturing through integrated chemistry expertise, safety-led development, impurity control, and regulatory-ready process optimization.
Learn more
AI & Computational Chemistry
Delivering integrated bioanalytical and pharmaceutical testing through advanced instrumentation, regulatory-aligned methodologies, and data integrity systems to accelerate development and global submissions.
Learn more
Process Safety Services
Ensuring safe and scalable manufacturing through early hazard identification, thermal risk assessment, powder safety evaluation, and globally aligned process safety frameworks.
Learn more
In Silico Genotoxicity
Applying ICH M7(R2)-aligned (Q)SAR modeling and expert toxicological review to assess impurity mutagenicity risks and generate regulatory-ready documentation.
Learn more
Clinical Supply Services
Enabling seamless clinical trial progression through GMP-compliant manufacturing, integrated API-to-dosage capabilities, and globally coordinated supply across all clinical phases.
Learn moreManufacturing Services
Commercial Supply Services
PI Health Sciences provides scalable EU GMP compliant commercial supply services, ensuring robust manufacturing, impurity control, regulatory alignment, and reliable global pharmaceutical supply.
Learn more
Clinical Development Services
Bridging laboratory research and clinical manufacturing through kilo-scale GMP production, enabling risk-aware scale up, technology transfer readiness, and regulatory aligned development.
Learn more
Pre-clinical Supply Services
Enabling early-stage drug development through scalable material manufacturing, integrated HPAPI capabilities, and globally aligned quality systems that support seamless clinical progression.
Learn moreCapabilities
Integrated Process R&D and Scalable Chemistry
Lifecycle-driven route optimization aligned with commercial manufacturing requirements.
Analytical Development and Regulatory-Ready Documentation
Validated analytical strategies supporting IND, NDA, and ANDA submissions.
Discovery-Aligned Process Safety and Risk Mitigation
Hazard assessment and thermal stability evaluation embedded within scale-up workflows.
Phase-Appropriate GMP Manufacturing
Seamless transition from preclinical batches to clinical and commercial production.
High Potency API Development up to OEB4
Controlled containment and safety-aligned handling for complex and high-potency compounds.
Lifecycle API Management and Cost Optimization
Efficient, high-yield routes designed for long-term supply sustainability and global compliance.
Frequently asked questions
We’re here to help with any questions you have about our plans, supported features, and how our model works.
How does PI Health Sciences integrate development and manufacturing within a single framework?
At PI Health Sciences, development and manufacturing are structurally aligned through integrated Process R&D, Analytical Sciences, Process Safety, and GMP manufacturing under unified governance. Each phase, from route scouting to commercial supply, is executed within a coordinated scientific model rather than siloed functions. This ensures that scalability, impurity control, exposure assessment, and regulatory compliance are evaluated simultaneously. The result is streamlined technology transfer, reduced scale-up risk, and accelerated progression toward global submissions.
How does our model reduce regulatory and scale-up risk across development stages?
Risk mitigation begins early through phase-specific route optimization, integrated safety studies prior to scale-up, and regulatory-aligned analytical validation strategies. Our teams proactively address impurity profiling, thermal stability, hazard identification, and documentation readiness to avoid late-stage surprises. By embedding ICH, USFDA, EU GMP, and global compliance considerations into each workflow, we minimize rework and regulatory deficiencies. This structured foresight strengthens submission confidence across IND, NDA, and commercial filings.
What capabilities support high-potency and complex molecule development?
PI Health Sciences offers integrated HPAPI development capabilities up to OEB4 within controlled and containment-aligned manufacturing environments. Our expertise spans complex chemistries, advanced reaction techniques, particle engineering, and chromatographic purification. Safety-aligned process design and hazard evaluation ensure exposure control without compromising scalability. These capabilities enable confident progression of oncology and other high-potency programs from early development through commercialization.
How are analytical and in silico assessments integrated into development workflows?
Analytical method development, impurity characterization, stability studies, and 21 CFR Part 11-compliant data systems are embedded directly within process development and manufacturing operations. In silico genotoxicity assessments aligned with ICH M7(R2) further strengthen impurity risk evaluation during early and late development. This integrated scientific approach ensures data integrity, defensible impurity classification, and submission-ready documentation. By linking predictive toxicology with validated analytical data, we enhance regulatory robustness and lifecycle continuity.
How does PI Health Sciences ensure seamless transition from preclinical to commercial supply?
Our phase-appropriate manufacturing model supports preclinical materials, clinical GMP production, kilo-scale IND-enabling batches, and large-scale commercial manufacturing within an interconnected infrastructure. Early process robustness, impurity control strategies, and scale-dependent risk mapping are designed to strengthen long-term supply stability. Integrated global supply coordination across India and Italy ensures continuity and compliance. This lifecycle-driven framework enables confident clinical advancement and sustained commercial reliability.
Contact Us
Connect with PI Health Sciences to learn how our integrated drug discovery solutions can advance your program from target identification to development candidate with speed, precision, and scientific confidence.